Air pollution is hypothesized to be a risk factor for diabetes. Epidemiological evidence is inconsistent and has not been systematically evaluated.

GENEVA, Switzerland (CMC) -- The World Health Organisation (WHO) is urging Caribbean countries to take urgent action to meet global targets to reduce the burden of non-communicable diseases (NCDs).

GENEVA, Switzerland (CMC) –The World Health Organization (WHO) is urging Caribbean countries to take urgent action to meet global targets to reduce the burden of non-communicable diseases (NCDs).

An urgent need exists to identify modifiable dietary risk factors for obesity in African-Americans. Human observations since the 1980’s of lower levels of 25-hydroxyvitamin D25(OH)D in obese than in nonobese individuals highlight a possible inverse relation between vitamin D and obesity.

Urgent government action is needed to meet global targets to reduce the burden of noncommunicable diseases (NCDs), and prevent the annual toll of 16 million people dying prematurely – before the age of 70 – from heart and lung diseases, stroke, cancer and diabetes, according to a new WHO report.

3 types of drugs to be tested

The search for effective treatments for obesity and its comorbidities is of prime importance. We previously identified ​IKK-ε and ​TBK1 as promising therapeutic targets for the treatment of obesity and associated insulin resistance. Here we show that acute inhibition of ​IKK-ε and ​TBK1 with ​amlexanox treatment increases ​cAMP levels in subcutaneous adipose depots of obese mice, promoting the synthesis and secretion of the cytokine ​IL-6 from adipocytes and preadipocytes, but not from macrophages.

Diabetes and hypertension is affecting at an alarming rate in both rural and urban populations in India and very few studies had been carried out among the tribal population. The objective of the study was to determine the prevalence rate of type 2 diabetes mellitus and hypertension and its associated risk factors among the tribal population in Salem District in Tamil Nadu.

Rapid lifestyle changes have increased the combined disease burden of diabetes and tuberculosis (TB) in rapidly urbanizing nations.

The US Food and Drug Administration (FDA) has approved diabetes drug Liraglutide (Saxenda, Novo Nordisk) for the treatment of obesity.

Pages